Dermatology Xagena News

Ixekizumab, an anti-IL-17 monoclonal antibody, met primary endpoint in phase II study in patients with chronic plaque psoriasis

Phase II data, published in the New England Journal of Medicine ( NEJM ), have showen that Ixekizumab, an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe p ...

Ixekizumab has maintained or has achieved high levels of skin clearance for patients with moderate-to-severe plaque psoriasis

The New England Journal of Medicine ( NEJM ) has published detailed results from three pivotal phase 3 studies, UNCOVER-1, UNCOVER-2 and UNCOVER-3, that have demonstrated the efficacy and safety of Ix ...

Treatment of psoriasis with Ixekizumab: an overview on efficacy

Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, is approved for the treatment of moderate-to-severe psoriasis. An overview has analyzed the efficacy o ...

Superiority of Ixekizumab, an IL-17A inhibitor, versus Guselkumab, an IL-23/p19 inhibitor, in delivering total skin clearance at week 12 in people with moderate to severe plaque psoriasis: IXORA-R trial

Ixekizumab ( Taltz ) met the primary and all major secondary endpoints up to week 12 in the phase 4 IXORA-R study, which evaluated the efficacy and safety of Ixekizumab versus Guselkumab ( Tremfya ) i ...

DermatologyNews.net

Search results for "Ixekizumab"

Ixekizumab, an anti-IL-17 monoclonal antibody, met primary endpoint in phase II study in patients with chronic plaque psoriasis

Ixekizumab has maintained or has achieved high levels of skin clearance for patients with moderate-to-severe plaque psoriasis

Treatment of psoriasis with Ixekizumab: an overview on efficacy

Superiority of Ixekizumab, an IL-17A inhibitor, versus Guselkumab, an IL-23/p19 inhibitor, in delivering total skin clearance at week 12 in people with moderate to severe plaque psoriasis: IXORA-R trial

MedTV